Denver, CONCT07129252Now EnrollingIRB Ready

SST2-positive Neuroendocrine Neoplasms Clinical Trial in Denver, CO

Access cutting-edge sst2-positive neuroendocrine neoplasms treatment through this clinical trial at a research site in Denver. Study-provided care at no cost to qualified participants.

Sponsored by Crinetics Pharmaceuticals Inc.

Quick Self-Assessment

See if you qualify for this Denver location

Preparing your pre-screening questions…

Expert Care in Denver

Access sst2-positive neuroendocrine neoplasms specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related sst2-positive neuroendocrine neoplasms treatment provided free

Apply for This Denver Location

Check if you qualify for this sst2-positive neuroendocrine neoplasms clinical trial in Denver, CO

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Denver

    Convenient for CO residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Denver site if eligible
  4. 4Begin participation

About This SST2-positive Neuroendocrine Neoplasms Study in Denver

This Phase 1/2, multicenter, open-label, FIH study aims to evaluate the safety, tolerability, PK, and preliminary antitumor activity of CRN09682 in participants with SST2-expressing NENs and other solid tumors. The study includes a Dose Escalation Phase to determine the MTD and DLTs. Following MTD identification, additional participants will be enrolled at the expansion dose to further assess safety, tolerability, PK, and antitumor activity.

Sponsor: Crinetics Pharmaceuticals Inc.

Who Can Participate

Inclusion Criteria

Have a histological diagnosis of metastatic or locally advanced inoperable NET, NEC, or other solid tumors that have confirmed radiological progression.
Have one or more measurable disease location per RECIST version 1.1.
Have a tumor that expresses SSR confirmed by SSR imaging.
Have an ECOG performance status of 0, 1, or 2.

Exclusion Criteria

Have tumor progression while undergoing a course of PRRT or within 6 months of completing PRRT.
Have brain metastases unless asymptomatic and stable for at least one month for participants with SCLC or LCLC or at least 3 months for participants with other non-NET solid tumors.
Use of anticancer agents within specified intervals prior to the first dose of study drug.
Had surgery, chemoembolization, or radiofrequency ablation within 90 days prior to first dose of study drug.
Prior participation in any intervention clinical study within 30 days or 5 half-lives (whichever is longer) prior to the first dose of study drug.
Participants with carcinoid syndrome.
Secondary malignancy: participants who have any other malignancy known to be active or treated within 3 years of the start of screening, with the exception of treated cervical intraepithelial neoplasia, superficial (noninvasive) bladder cancer, and non-melanoma skin cancer.
Have prior treatment with MMAE.
Have hypersensitivity or history of anaphylactic reaction to octreotide, other SSAs, and/or MMAE.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Denver?

Yes, this clinical trial (NCT07129252) has an active research site in Denver, CO that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

SST2-positive Neuroendocrine Neoplasms Treatment Options in Denver, CO

If you're searching for sst2-positive neuroendocrine neoplasms treatment options in Denver, CO, this clinical trial (NCT07129252) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Denver research site is actively enrolling participants for this clinical trial. You'll receive care from experienced sst2-positive neuroendocrine neoplasms specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all sst2-positive neuroendocrine neoplasms clinical trials near you to find additional studies recruiting in your area.

More Multiple Sclerosis Trials in Denver, CO

See all multiple sclerosis clinical trials recruiting in Denver — not just this study.

Browse Multiple Sclerosis Trials in Denver →

Browse More Trials by Condition

Multiple Sclerosis TrialsAnkylosing Spondylitis TrialsAll Conditions →

Ready to Join in Denver?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Denver, CO